MEETING REPORT

WHO technical consultation:
Nutrition-related health products and the
World Health Organization Model
List of Essential Medicines —
practical considerations and feasibility

Geneva, Switzerland 20–21 September 2018





MEETING REPORT

WHO technical consultation:
Nutrition-related health products
and the World Health Organization
Model List of Essential Medicines –
practical considerations and
feasibility

Geneva, Switzerland 20–21 September 2018



WHO technical consultation: Nutrition-related health products and the *World Health Organization Model List of Essential Medicines* – practical considerations and feasibility. Geneva, Switzerland, 20–21 September 2018. Meeting report

WHO/NMH/NHD/19.1

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO technical consultation: Nutrition-related health products and the *World Health Organization Model List of Essential Medicines* – practical considerations and feasibility, Geneva, Switzerland, 20–21 September 2018. Meeting report. (WHO/NMH/NHD/19.1). Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The named authors of the meeting presentations and background papers alone are responsible for the views expressed in this publication.

This publication contains the report of the WHO technical consultation: Nutrition-related health products and the *World Health Organization Model List of Essential Medicines*: practical considerations and feasibility, 20 –21 September 2018 and does not necessarily represent the decisions or policies of WHO.

Cover design and layout: Alberto March (Barcelona, Spain)

CONTENTS

ABBRE	VIATIONS	IX	
ACKNOWLEDGEMENTS		X	
	Financial support	X	
EXECUT	TIVE SUMMARY	1	
INTROD	DUCTION	4	
MANAG	GEMENT OF CONFLICTS OF INTEREST	6	
SUMMA	UMMARY OF MEETING PRESENTATIONS		
	The World Health Organization Model List of Essential Medicines and criteria for selection	7	
•	Review of nutrition-related health products currently listed as essential medicines in the World Health Organization Model List of Essential Medicines and Model List of Essential Medicines for Children	8	
•	World Health Organization guidelines pertaining to essential nutrition actions that require nutrition-related health products	9	
•	Panel discussion: Public health sector perspective on the regulatory aspects of nutrition-related health products	14	
•	World Health Organization food safety considerations related to nutrition-related health products	18	
•	International guidelines and standards in the production of foods for special dietary uses and foods for special medical purposes	19	
	Therapeutic and supplementary foods in the management of acute undernutrition	20	
•	Expert assessments of the inclusion of ready-to-use therapeutic foods in the World Health Organization Model List of Essential Medicines: lessons learnt from a qualitative evaluation	22	
•	Stakeholder perceptions of adding ready-to-use therapeutic foods and other nutrition-related products to the World Health Organization Model List of Essential Medicines	22	
•	Process and impact of integration of ready-to-use therapeutic foods in national essential medicines lists	23	
•	Public health relevance of including specialized nutrition-related health products in the South Sudan National Essential Medicine List 2018	24	
•	The road to sustainable availability of ready-to-use therapeutic foods for the management of acute undernutrition in the Plurinational State of Bolivia	25	
•	Panel discussion: Challenges at the country level in access to nutrition-related health products, with a focus on purchasing and production	25	

GENERAL	DISCUSSIONS	28
•	Public health importance and efficacy of ready-to-use therapeutic foods	28
•	Access to, availability of and prioritization of ready-to-use therapeutic foods	29
•	Regulation and product quality of ready-to-use therapeutic foods	29
	SCUSSION ON PRACTICAL CONSIDERATIONS AND FEASIBILITY OF INCLUDING NUTRITION-RELATED PRODUCTS IN ESSENTIAL MEDICINES LISTS	30
REFEREN	CES	31
ANNEX 1.	LIST OF PARTICIPANTS	36
ANNEX 2.	AGENDA	43
ANNEX 3.	BACKGROUND PAPERS	45
A3.1	Expert assessments of the inclusion of ready-to-use therapeutic foods in the World Health Organization Model List of Essential Medicines: lessons learnt from a qualitative evaluation	45
A3.2	Stakeholder perceptions of adding ready-to-use therapeutic foods and other nutrition-related products to the World Health Organization Model List of Essential Medicines	68
A3.3	Process and impact of integration of ready-to-use therapeutic foods in national essential medicines lists	88
A3.4	Public health relevance of including specialized nutrition-related health products in the South Sudan Essential Medicine List 2018	106
A3.5	The road to sustainable availability of ready-to-use therapeutic foods for the management of acute malnutrition in the Plurinational State of Bolivia	119

WHO TECHNICAL CONSULTATION: NUTRITION-RELATED HEALTH PRODUCTS AND THE WORLD HEALTH ORGANIZATION MODEL LIST OF ESSENTIAL MEDICINES — PRACTICAL CONSIDERATIONS AND FEASIBILITY

ABBREVIATIONS

ANVISA Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency), Brazil

COFEPRIS Federal Commission for Protection against Sanitary Risk, Mexico

EML WHO Model List of Essential Medicines

EMLc WHO Model List of Essential Medicines for Children

FAO Food and Agriculture Organization of the United Nations

GPW13 World Health Organization Thirteenth General Programme of Work 2019–2023

GRADE Grading of Recommendations, Assessment, Development and Evaluation

RUSF Ready-to-use supplementary food

RUTF Ready-to-use therapeutic food

UNICEF United Nations Children's Fund

USAID United States Agency for International Development

WHO World Health Organization

ACKNOWLEDGEMENTS

This meeting report was prepared by the World Health Organization (WHO) Department of Nutrition for Health and Development. Mr Filiberto Beltran-Velazquez and Dr Maria Nieves Garcia-Casal led the organization of the meeting and the preparation of the document, under the supervision of Dr Juan Pablo Peña-Rosas. Dr Damian Francis was commissioned by WHO as a meeting rapporteur. WHO acknowledges the technical contributions of the following individuals (in alphabetical order): Dr Francesco Branca, Ms Bernadette Capello, Dr Nicola Magrini, Dr Lorenzo Moja, Mr Kim Petersen, Dr Pura Rayco-Solon, Dr Lisa Rogers, Dr Nigel Rollins and Ms Zita Weise Prinzo. Thanks are also due to the following WHO regional advisers who supported the organization of the meeting (in alphabetical order): Dr Ayoub Al-Jawaldeh (Eastern Mediterranean Region), Dr Angela De Silva (South-East Asia Region), Dr Ruben Grajeda (Region of the Americas), Dr Adelheid Onyango (African Region) and Dr Juliawati Untoro (Western Pacific Region).

Ms Loubna Al Atlassi from the Department of Partnerships and non-State Actors provided support in relation to the *Framework of engagement with non-state actors* and Ms Alma Alic from the Department of Compliance and Risk Management and Ethics provided support in the management of the conflicts of interest procedures. Ms Rosa A Seminario from the Department of Nutrition for Health and Development provided logistic support for the meeting.

Financial support

WHO gratefully acknowledges the contribution of Nutrition International (Canada) and the Bill & Melinda Gates Foundation (United States of America), for providing financial support to cover the costs of the WHO Secretariat for convening the technical consultation and publication of this report.

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 25326



